TABLE 4.

Distributions of the average CNI trough levels (ng/mL) over 0–60, 0–120, and 0–180 months post‐transplant by treatment arm.

Drug	During post‐tx months	Mean ± SE (median, interquartile range)
		Group A		Group B		Group C
		N	TAC/SRL	N	TAC/MMF	N	CSA/SRL	p value a
TAC level:	0–60	35	6.75 ± 0.14 [6.80, 6.49–7.27]	32	7.27 ± 0.17 [7.01, 6.68–7.85]	10 b	6.88 ± 0.36 [7.10, 5.89–7.73]	0.02
	0–120	19	6.26 ± 0.21 [6.11, 5.70–6.73]	22	6.60 ± 0.24 [6.65, 6.21–6.97]	9 b	6.56 ± 0.34 [6.78, 6.45–7.22]	0.30
	0–180	13	5.92 ± 0.27 [6.03, 5.44–6.49]	15	6.46 ± 0.14 [6.40, 5.88–6.89]	4 b	5.93 ± 0.29 [6.00, 5.45–6.40]	0.09
CSA level:	0–60					29	154.2 ± 5.9 [150.7, 135.6–160.6]
	0–120					21	136.1 ± 4.9 [133.5, 123.4–143.9]
	0–180					10	134.8 ± 5.1 [133.5, 127.1–139.6]

Abbreviations: CNI, calcineurin inhibitor; CSA, cyclosporine microemulsion; MMF, mycophenolate mofetil; SE, standard error; SRL, sirolimus; TAC, tacrolimus; tx, transplant.

^a The p values listed in this column represent t‐test results comparing the group A versus B average TAC trough levels during 0–60, 0–120, and 0–180 months post‐transplant, respectively.

^b A total of 11 patients had switched from CSA to TAC, 6 during the first 0–6 months post‐transplant, 3 during the first 6–12 months post‐transplant, and 2 beyond 12 months post‐transplant.